

JUBILANT LIFE SCIENCES (BVI) LTD
Balance Sheet

As at 31st Mar	Notes No	2014		2013	
		USD	INR (' In Thousands)	USD	INR (' In Thousands)
I. EQUITY AND LIABILITIES					
Shareholders' Funds					
Share capital	1	3,972,501	198,793	3,927,501	196,372
Reserves & surplus	2	(25,505)	37,671	(19,602)	15,787
		3,946,996	236,465	3,907,899	212,160
Current liabilities					
Trade payables	3	1,661	99	-	-
Other current liabilities	4	-	-	989	54
		1,661	99	989	54
Total					
		3,948,657	236,564	3,908,888	212,214
II. ASSETS					
Non-current investments					
	5	3,944,502	236,315	3,904,502	211,975
		3,944,502	236,315	3,904,502	211,975
Current assets					
Cash & bank balances	6	3,926	235	4,159	227
Short-term loans and advances	7	229	14	227	12
		4,155	249	4,386	239
Total		3,948,657	236,564	3,908,888	212,214

Rajneesh Gupta
Head Accounts
Place : Noida
Date : 22nd May 2014

JUBILANT LIFE SCIENCES (BVI) LTD
Statement of Profit and Loss

For the year ended 31st March,	Notes No	2014	2014	2013	2013
		USD	INR (' In Thousands)	USD	INR (' In Thousands)
EXPENSES					
Other expenses	8	5,902	358	4,491	244
Total expenses		5,902	358	4,491	244
Profit for the Year		(5,902)	(358)	(4,491)	(244)

Rajneesh Gupta
Head Accounts
Place : Noida
Date : 22nd May 2014

JUBILANT LIFE SCIENCES (BVI) LTD**CASH FLOW STATEMENT**

For the year ended 31st March,

	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
A. Cash flows from operating activities				
Net income before minority interest	(5,902)	(358)	(4,491)	(244)
Operating profit before working capital changes	(5,902)	(358)	(4,491)	(244)
Adjustments for :				
(Increase)/Decrease in trade and other receivables	(3)	(0)	1,299	70
Increase/(Decrease) in trade and other payables	672	41	989	54
Net cash inflow/(outflow) in course of operating activities	(5,233)	(318)	(2,204)	(120)
B. Cash flow arising from investing activities :				
(Purchase)/sale of investments (net)(Including in Subsidiaries)	(40,000)	(2,416)	(12,500)	(679)
Net cash inflow/(outflow) in course of investing activities	(40,000)	(2,416)	(12,500)	(679)
C. Cash flow arising from financing activities :				
Proceeds from issue of share capital(including share premium & net of share issue expenses)	45,000	2,718	12,500	679
Net cash inflow/(outflow) in course of financing activities	45,000	2,718	12,500	679
D. Foreign currency translation difference arising on consolidation		25		22
Net Increase in cash & cash equivalents (A+B+C+D)	(233)	9	(2,204)	(98)
Add: cash & cash equivalents at the beginning of year(including balance in dividend accounts)	4,159	226	6,363	324
Cash & cash equivalents at the close of the year(including balance in dividend accounts)	3,926	235	4,159	226

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".

Rajneesh Gupta

Head Accounts

Place : Noida

Date : 22nd May, 2014

JUBILANT LIFE SCIENCES (BVI) LTD
Notes to the Financial Statements

As at 31st Mar	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
1. SHARE CAPITAL				
Authorized				
10,000,000 equity shares of USD 1 each (Previous Year 10,000,000 equity shares of USD 1 each)	-	-	-	-
Issued & Subscribed				
3,972,501 equity shares of USD 1 each (Previous Year 3,927,501 equity shares of USD 1 each)	-	-	-	-
Paid up				
3,972,501 equity shares of USD 1 each (Previous Year 3,927,501 equity shares of USD 1 each)	3,972,501	198,793	3,927,501	196,372
	3,972,501	198,793	3,927,501	196,372

1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts, if any, in proportion of their shareholding. However, no such preferential amounts exist currently.

3) The details of shareholders holding more than 5% shares in the company :

As at 31st Mar	2014	2014	2013	2013
Name of the shareholder	No of shares	% held	No of shares	% held
Drug Discovery and Development Solutions Ltd	3,972,501	100%		
Jubilant Pharma PTE Ltd			3,927,501	100%

4) The reconciliations of number of shares outstanding at beginning and at the end of reporting period

As at 31st Mar	2014	2014	2013	2013
Particulars	No	INR (' In Thousands)	No	INR (' In Thousands)
Numbers of shares at the beginning	3,927,501	196,372	3,915,001	195,672
Add: Shares issued during the year	45,000	2,421	12,500	700
Numbers of shares at the end	3,972,501	198,793	3,927,501	196,372

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31st Mar	2014	2014	2013	2013
Name of the shareholder	No	INR (' In Thousands)	No	INR (' In Thousands)
Drug Discovery and Development Solutions Ltd, Singapore Holding company 3,972,501 equity shares of USD 1 each	3,972,501	198,793		
Jubilant Pharma Pte Ltd, Singapore (Previous Year 3,927,501 equity shares of USD 1 each)			3,927,501	196,372

JUBILANT LIFE SCIENCES (BVI) LTD
Notes to the Financial Statements

As at 31st Mar	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
2. RESERVES AND SURPLUS				
Foreign Currency Translation Reserve				
Foreign Currency Translation Reserve Opening	-	16,739	-	3,442
Foreign Currency Translation Reserve During the Year	-	22,242	-	13,297
	-	38,981	-	16,739
Surplus as per P&L Account				
As per last Balance Sheet	(19,603)	(952)	(15,111)	(708)
Add: Net Profit after tax transferred from Statement of Profit and Loss	(5,902)	(358)	(4,491)	(244)
	(25,505)	37,671	(19,602)	15,787
3. TRADE PAYABLES				
Trade payables-others	1,661	99	-	-
	1,661	99	-	-
4. OTHER CURRENT LIABILITIES				
Other payables	-	-	989	54
	-	-	989	54
5. NON-CURRENT INVESTMENTS				
Investment in Subsidiary/ Fellow subsidiaries Companies				
Jubilant Biosys (BVI) Ltd.	1,397,501	83,724	1,377,501	74,785
1,397,501 shares (previous year 1,377,501 shares) of USD 1 each				
Jubilant Drug Development Pte. Ltd.	2,547,001	152,591	2,527,001	137,191
2,547,001 shares (previous year 2,527,001 shares) of USD 1 each				
	3,944,502	236,315	3,904,502	211,975
6. CASH AND BANK BALANCES				
Cash and cash equivalents				
Balances with banks:				
- On current accounts	3,926	235	4,159	226
	3,926	235	4,159	226
7. SHORT TERM LOANS AND ADVANCES				
- Others	229	14	226	12
	229	14	226	12
8. OTHER EXPENSE				
Legal , professional & consultancy charges	5,762	350	4,431	241
Bank Charges	140	8	60	3
	5,902	358	4,491	244